OCX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
OCX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
OncoCyte's sale of investment for the three months ended in Sep. 2024 was $0.00 Mil. It means OncoCyte gained $0.00 Mil from selling investments. OncoCyte's sale of investment for the trailing twelve months (TTM) ended in Sep. 2024 was $0.00 Mil.
Compared with last quarter ($0.00 Mil in Jun. 2024 ), OncoCyte gained the same money from selling investments in Sep. 2024 ($0.00 Mil).
The historical data trend for OncoCyte's Sale Of Investment can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OncoCyte Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Sale Of Investment | Get a 7-Day Free Trial | - | - | - | - | 0.37 |
OncoCyte Quarterly Data | ||||||||||||||||||||
Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | Jun24 | Sep24 | |
Sale Of Investment | Get a 7-Day Free Trial | - | - | - | - | - |
Sale of Investments represents cash inflow on the sale of investments in securities.
Sale Of Investment for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of OncoCyte's Sale Of Investment provided by GuruFocus.com. Please click on the following links to see related term pages.
Broadwood Partners Lp | 10 percent owner | BROADWOOD CAPITAL INC., 142 WEST 57TH STREET, 11TH FLOOR, NEW YORK NY 10019 |
Andrew Arno | director | C/O MERRIMAN CURHAN FORD GROUP, INC., 600 CALIFORNIA STREET, 9TH FLOOR, SAN FRANCISCO CA 94108 |
Josh Riggs | officer: Interim CEO | 15 CUSHING, IRVINE CA 92618 |
John Peter Gutfreund | other: Former Director | 767 5TH AVENUE, 44TH FLOOR, NEW YORK NY 10153 |
Alfred D Kingsley | director | 150 E 57TH STREET, NEW YORK NY 10022 |
Pura Vida Investments, Llc | 10 percent owner | 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011 |
Lou Silverman | director | |
James Yang Liu | officer: Controller, PAO | C/O ONCOCYTE CORPORATION, 15 CUSHING, IRVINE CA 92618 |
Andrew J. Last | director | 3420 CENTRAL EXPRESSWAY, SANTA CLARA CA 95051 |
Jennifer L. Carter | director | C/O DFP SPONSOR LLC, 780 THIRD AVENUE, 37TH FLOOR, NEW YORK NY 10017 |
Ronald Asbury Andrews | director | 5791 VAN ALLEN WAY, CARLSBAD CA 92008 |
Melinda Griffith | director | 1010 ATLANTIC AVENUE, SUITE 102, ALAMEDA CA 94501 |
Anish M. John | officer: SVP, Finance, and Interim CFO | C/O ONCOCYTE CORPORATION,, 15 CUSHING, IRVINE CA 92618 |
Li Yu | officer: VP Cntrllr/Prncpl Acctng Offcr | 120 NEWPORT CENTER DRIVE., NEWPORT BEACH CA 92660 |
Efrem Kamen | 10 percent owner | C/O PURA VIDA INVESTMENTS, LLC, 512 W 22ND STREET, 7TH FLOOR, NEW YORK NY 10011 |
From GuruFocus
By GuruFocus News • 11-13-2024
By Marketwired • 08-01-2024
By GuruFocus News • 11-13-2024
By Marketwired • 11-12-2024
By Marketwired • 08-05-2024
By ACCESSWIRE • 08-14-2024
By Marketwired • 06-03-2024
By GuruFocus News • 11-12-2024
By Marketwired • 06-17-2024
By GuruFocus News • 11-14-2024
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.